Bone Biologics Corp (BBLG) — Cash Flow-to-Debt Ratio
Bone Biologics Corp (BBLG) has a Cash Flow-to-Debt Ratio of -1.71x as of December 2025, meaning its operating cash flow of $-714.76K could theoretically repay -2% of its total liabilities ($418.59K) in one year. Check BBLG cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bone Biologics Corp Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Bone Biologics Corp across 14 annual periods. Also explore Bone Biologics Corp asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Bone Biologics Corp (2012–2025)
Year-by-year debt coverage analysis for Bone Biologics Corp. For market capitalisation and broader financial context, see market value of Bone Biologics Corp.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.43x | $-2.69 Million | $418.59K | ▲ +41.1% |
| 2024 | -10.92x | $-4.12 Million | $377.71K | ▲ +5.0% |
| 2023 | -11.49x | $-9.56 Million | $831.40K | ▼ -721.0% |
| 2022 | -1.40x | $-3.57 Million | $2.55 Million | ▲ +88.6% |
| 2021 | -12.30x | $-1.23 Million | $99.91K | ▼ -39338.3% |
| 2020 | -0.03x | $-426.93K | $13.69 Million | ▲ +88.6% |
| 2019 | -0.27x | $-3.25 Million | $11.90 Million | ▲ +35.8% |
| 2018 | -0.43x | $-4.10 Million | $9.64 Million | ▼ -17.5% |
| 2017 | -0.36x | $-3.33 Million | $9.19 Million | ▲ +52.5% |
| 2016 | -0.76x | $-7.33 Million | $9.61 Million | ▼ -67.0% |
| 2015 | -0.46x | $-3.55 Million | $7.76 Million | ▼ -24.7% |
| 2014 | -0.37x | $-2.76 Million | $7.52 Million | ▼ -34024.3% |
| 2013 | 0.00x | $-6.12K | $5.70 Million | ▲ +98.9% |
| 2012 | -0.10x | $-447.00 | $4.68K | — |